Interestingly, clinical remission induced by B-cell depletion with rituximab (which targets CD20) reduces the numbers of CD4+ CTLs in blood and affected organs in IgG4-RD (24), (25). The gene discussed is CD4; the disease is immunoglobulin G4-related sclerosing disease.